Navigation Links
Sunesis Pharmaceuticals to Present Interim Clinical Data From Voreloxin (Formerly SNS-595) Ovarian Cancer Trial at 44th ASCO Annual Meeting and Acute Myeloid Leukemia Trials at 13th EHA Congress
Date:5/28/2008

SOUTH SAN FRANCISCO, Calif., May 28 /PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) will present data from ongoing clinical trials of voreloxin (formerly SNS-595) at two major upcoming oncology conferences.

Updated interim data from Sunesis' ongoing Phase 2 clinical trial of voreloxin in platinum-resistant ovarian cancer patients will be presented during the 44th American Society of Clinical Oncology (ASCO) Annual Meeting being held May 30 - June 3, 2008 in Chicago, Illinois.

Updated results and a comparative safety and response analysis in older patients (>/= 60 years old) and younger patients (< 60 years old) from the company's Phase 1 clinical trial of voreloxin in relapsed or refractory acute leukemia patients will be presented at the 13th Congress of the European Hematology Association (EHA) being held June 12 - 15, 2008 in Copenhagen, Denmark. The presentation will also include preliminary data from the company's Phase 1b trial of voreloxin combined with cytarabine in relapsed/refractory acute myeloid leukemia (AML) patients. In addition, data from the company's ongoing Phase 1 clinical trial of SNS-032 in patients with chronic lymphocytic leukemia and multiple myeloma will be presented at EHA.

44th ASCO Annual Meeting

o A PHASE 2 TRIAL OF SNS-595 IN WOMEN WITH PLATINUM RESISTANT EPITHELIAL

OVARIAN CANCER

Abstract #5582

General poster session Gynecologic Cancer: Ovarian Cancer

Saturday, May 31, 2008, 8:00 a.m. - 12:00 p.m. CST, S Hall A1

13th Congress of the European Hematology Association

o SAFETY AND EFFICACY EXPERIENCE OF SNS-595 IN RELAPSED/REFRACTORY ACUTE

LEUKEMIA PATIENTS >/= 60 YEARS OLD COMPARED TO < 6
'/>"/>

SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Sunesis Pharmaceuticals Commences Clinical Trials of SNS-595 and SNS-314
2. Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference
3. Sunesis Pharmaceuticals to Present Data on Two Product Candidates at the 49th Annual Meeting of the American Society of Hematology
4. Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
5. Sunesis Pharmaceuticals to Present Non-Clinical Data at the Annual Meeting of the American Association for Cancer Research
6. Sunesis Pharmaceuticals Reports Data from Nonclinical Studies of SNS-032 at the Annual Meeting of the American Association for Cancer Research
7. Sunesis Pharmaceuticals Initiates Phase 2 Clinical Trial of Voreloxin (SNS-595) in Acute Myeloid Leukemia
8. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
9. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
10. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2009)..., ATLANTA, Dec. 1 Cry...ical device and cardiovascular tissue processing c...or 2010. ,, The Company expects total revenues ...lion and $123.0 million, which includes between $1...eived from the Department of Defense in connection...
(Date:12/1/2009)..., GLEN BURNIE, Md., Dec. 1 Sleep ...c service provider for home testing and evaluation... has named Richard Hassett, M.D., as its chief exe...nt of Matria Healthcare, during its growth from a ...0 million industry leader in total population heal...
(Date:12/1/2009)... , CHICAGO, Dec. 1 At this yea...North America (RSNA), Royal Philips Electronics ( ...Workspace, a set of solutions that provides radiol... images at one workspot to help drive quality and ...are, Philips will also highlight new capabilities ...
Breaking Medicine Technology:CryoLife Provides Initial 2010 Financial Guidance 2CryoLife Provides Initial 2010 Financial Guidance 3CryoLife Provides Initial 2010 Financial Guidance 4CryoLife Provides Initial 2010 Financial Guidance 5Sleep Solutions, Inc. Names Richard Hassett, M.D., New CEO 2Sleep Solutions, Inc. Names Richard Hassett, M.D., New CEO 3Philips Introduces Multi-Modality Breast Workspace to Complement Comprehensive Portfolio of Diagnostic Imaging Solutions for Breast Care 2Philips Introduces Multi-Modality Breast Workspace to Complement Comprehensive Portfolio of Diagnostic Imaging Solutions for Breast Care 3Philips Introduces Multi-Modality Breast Workspace to Complement Comprehensive Portfolio of Diagnostic Imaging Solutions for Breast Care 4Patients who Participated in Pleio GoodStart 28TM 29 Refilled 30 25 Sooner and 40 25 More Averaging 2 Additional Rx Refills per Patient 5720 1Patients who Participated in Pleio GoodStart 28TM 29 Refilled 30 25 Sooner and 40 25 More Averaging 2 Additional Rx Refills per Patient 5720 2Growing Threat of Substandard and Counterfeit Medicines in Developing Countries Addressed by New USAID USP Cooperative Agreement 60120 1Growing Threat of Substandard and Counterfeit Medicines in Developing Countries Addressed by New USAID USP Cooperative Agreement 60120 2Growing Threat of Substandard and Counterfeit Medicines in Developing Countries Addressed by New USAID USP Cooperative Agreement 60120 3Growing Threat of Substandard and Counterfeit Medicines in Developing Countries Addressed by New USAID USP Cooperative Agreement 60120 4Growing Threat of Substandard and Counterfeit Medicines in Developing Countries Addressed by New USAID USP Cooperative Agreement 60120 5AHIP Statement on Government Run Plan 60115 1AHIP Statement on Government Run Plan 60115 2AHIP Statement on Government Run Plan 60115 3
... DUBLIN, Calif., July 1 SuperGen Inc. (Nasdaq:,SU...covery, rapid,development and commercialization of...gnancies, today commented on the preliminary effic...g Dacogen(R) (decitabine) for,Injection to best su...dysplastic syndromes (MDS). The data did not demon...
...,Inc. (Amex: ANX ) today announced preliminary re...clinical trial of ANX-510, or CoFactor, the Compan...cil), for the treatment of,first-line metastatic c...y,was progression-free survival, which is expected...th safety data later this year., Data from the 85...
Other Medicine Technology:SuperGen Comments on Preliminary Efficacy Update on EORTC Phase 3 Trial of Dacogen(R) Versus Supportive Care in Patients With Myelodysplastic Syndromes 2SuperGen Comments on Preliminary Efficacy Update on EORTC Phase 3 Trial of Dacogen(R) Versus Supportive Care in Patients With Myelodysplastic Syndromes 3SuperGen Comments on Preliminary Efficacy Update on EORTC Phase 3 Trial of Dacogen(R) Versus Supportive Care in Patients With Myelodysplastic Syndromes 4ADVENTRX Announces Preliminary Response Rate Data From Discontinued Phase 3 Trial of CoFactor(R) 2ADVENTRX Announces Preliminary Response Rate Data From Discontinued Phase 3 Trial of CoFactor(R) 3ADVENTRX Announces Preliminary Response Rate Data From Discontinued Phase 3 Trial of CoFactor(R) 4
(Date:12/1/2009)...g behaviors jump from friend to friend , ... suggests that lonely people attract fellow "lonel..., "Loneliness can spread from person to person to ... James H. Fowler, co-author of the study published...ity and Social Psychology , and professor of polit...
(Date:12/1/2009)... medical, legal or business requiring dictation an...s week with the release of ,DictateOnTheGo, for Ap...liday weekend, allows anyone required to dictate a...d seamlessly using just the iPhone 3G device. , ... The iPhone App, released by Florida based Rocket ...
(Date:12/1/2009)...wire-FirstCall/ -- Air Products (NYSE: APD ) tod...sale of the assets of its polyurethane pre-polymer...Versathane® tradenames to COIM USA Inc., a fu...als producer COIM SpA. ,, Included in the sale...boro, N.J. Terms of the agreement are not being di...
(Date:12/1/2009)... Abrazo Media Relations-- The Center for Pediatric...opaedics.com ) located in Mesa, Arizona announces ...all to its practice. ,, Dr. Udall is trained i...cently completing his fellowship training at Harva...cused on adult and pediatric orthopaedic sports me...
(Date:12/1/2009)...will honor The Forsyth Institute with an Outstandi...n to be held on February 27, 2010, in Washington, ...on & Exhibition. The William J. Gies Awards for Vi...butions to, and support of global oral health and ...ies Award winners, visit www.adeagiesfoundation.o...
Breaking Medicine News(10 mins):Health News:Loneliness May Be Catching 2Health News:Loneliness May Be Catching 3Health News:Medical and Legal Professionals Find Relief Leveraging Apple iPhone App for Dictation and Transcription 'On the Go' 2Health News:Air Products Completes Sale of Polyurethane Pre-Polymers Business to COIM USA 2Health News:Orthopaedic Surgeon Dr. J. Hunt Udall Joins the Center for Pediatric Orthopaedics and Scoliosis as One of Few Trained Doctors to Perform Minimally Invasive Hip Arthroscopy 2Health News:The Forsyth Institute receives the William J. Gies Award for outstanding achievement 2
...hosts annual wine auction; honors Robert,Mondavi a...O, Calif., Oct. 9 Silicon,Valley professionals, C...ents band together to bring hearing to those livin... October 9, 2008 at,6:00 p.m., dinner will be prep...
...Nature,s Way Holding Company, a,subsidiary of Germ...ading,worldwide producer of clinically proven phyt...utstanding shares of Enzymatic Therapy with North,...,provides for customary conditions to closing., T...
... Carolina Institute for Public Health has been awa...new research center focused on helping protect the... , The institute, part of the University of North...of seven new Preparedness and Emergency Response R...
... Volunteers in Medicine is easing the pain of the...the country. , Burlington...ities across the country, 250,000+ retired physici... to promote and guide the development of a nationa...
... team create world-renowned haunted house to,benef.... 9 Led by internationally-renowned,"airigamist" ...over the,world and hundreds of community volunteer...lease visit, http://www.balloonmanor.com for tick...
... brings rehabilitation services to Mesa, BIRMINGH...HLS ) today announced it has broken ground on Heal...ew, 40-bed freestanding inpatient,rehabilitation h...since 1995 and,look forward to offering HealthSout...
Other Medicine News:Health News:Local Leaders Support Needy Individuals, Communities 2Health News:Schwabe, World Leader in Herbal Manufacturing Will Acquire Enzymatic Therapy Through Nature's Way Holding, Inc. 2Health News:Schwabe, World Leader in Herbal Manufacturing Will Acquire Enzymatic Therapy Through Nature's Way Holding, Inc. 3Health News:UNC receives $8.5 million for new public health preparedness research center 2Health News:Free Clinics Now Providing Healthcare Solutions to the Uninsured 2Health News:Free Clinics Now Providing Healthcare Solutions to the Uninsured 3Health News:Balloon Manor Reappears in Rochester 2Health News:HealthSouth Announces Plans to Build New Hospital in Arizona 2Health News:HealthSouth Announces Plans to Build New Hospital in Arizona 3
UltraClean™ Agarose
...rose 1000 is specifically formulated for high reso.... This standard melting temperature agarose can re...ence in size. UltraPure™ Agarose 1000 gels ... and improved clarity for enhanced visibility of f...
Agarose IEF
Agarose, separation > 500 bp, Genetic Performance Certified †
Medicine Products: